Introduction
failure requiring chronic haemodialysis in 1986. His adjuvant treatment combined 1.5 g/d calcium carbonMacroprolactinomas do not seem to be more frequent ate, 2 g/d aluminium hydroxide, 500 mg/d furosemide in end-stage renal failure than in the general popand 122 mg/d ferrous fumarate. ulation. Nevertheless mild hyperprolactinaemia is
In October 1993, he complained of progressive common in patients with chronic renal failure (CRF ).
impairment of visual acuity in the right eye, a sensation The prevalence of hyperprolactinaemia in CRF cases of breast tension without gynecomastia or galacranges between 20 and 75% [1] [2] [3] . In mild to moderate torrhoea, and impairment of sexual potency. At admis-CRF, prolactin (PRL) levels are usually <100 ng/ml, sion, visual acuity was 6/10. The visual field showed although higher levels up to 2000 ng/ml have been exclusion of a blind spot. No sign of global pituitary reported in cases of hyperprolactinaemia secondary to deficiency or polyuria/polydipsy was observed. drug intake. In patients undergoing dialysis, PRL levels Pituitary magnetic resonance imaging (MRI ) are >100 ng/ml in 14% of cases, sometimes reaching showed a 3×3.5×3.5 cm tumour invading the right 300-400 ng/ml [3] . After dialysis, PRL levels in such cavernous sinus and the chiasmatic cistern. The diapatients remain unchanged or slightly increased [4] , gnosis of PRL-secreting pituitary macroadenoma was whereas after renal transplantation, basal or stimulated confirmed since the PRL level was 72 600 ng/ml PRL levels become perfectly normal [4] [5] [6] . The mech-(normal range <18 ng/ml ). A blunted response to the anisms leading to hyperprolactinaemia in CRF are thyreotropin ( TRH ) stimulation-test (increase of PRL unknown. One has to consider a decrease in PRL <100% after 200 mg of TRH IV ), was found together metabolic clearance rate (MCR) and/or disturbed with a reduced testosterone level (1 ng/ml; normal hypothalamic regulation of PRL synthesis and release.
range: 4-8 ng/ml ), a normal estradiol level (10 pg/ml; The demonstration of impaired acute suppression by normal range: 10-40 pg/ml ), normal gonadotropins dopaminergic agonists supports the hypothesis of laclevels (LH=5.5 IU/l; normal range: 2-12 IU/l, FSH= totroph dysregulation [5] [6] [7] . The response of prolactin-4.65 IU/l; normal range: 2-12 IU/l ) with a normal omas to dopaminergic agonist therapy in patients response to LHRH (LH=5.5-20.6 IU/l, FSH= undergoing haemodialysis and its evolution after trans-4.65-7.4 IU/l ), partial thyrotropin deficiency (T4= plantation could never be studied. We describe here 7 pg/ml; normal range: 9-16 pg/ml, T3=3.9 pg/ml; the case of a patient with chronic renal failure and normal range: 2.4-5.3 pg/ml and TSH=1.6 UI/l; macroprolactinoma which was partially resistant to 15 mg/day bromocriptine before transplantation and normal range: 0.5-3 UI/l ). Cortisol level was normal became responsive thereafter.
at 23.5 mg/dl, with a normal ACTH level at 61 pg/ml and a normal response to corticotropin releasing factor. GH secretion was normal. The final diagnosis was invasive PRL-secreting macroadenoma combined with Correspondence and offprint requests to: Dr Philippe Touraine, partial gonadotropin and thyrotropin deficiency. 15 mg/day), testosterone (250 mg/month IM ) and -the tumour had shrunk from 3×3.5×3.5 cm to 2.2×3.0×3.0 cm with partial hemorrhagic necrosis; its thyroxine (100 mg/day). The patient's visual acuity and sexual potency improved rapidly despite the persistence involution continued on the last MRI performed in June 1996. of hyperprolactinaemia. Indeed, PRL levels remained above 10 000 ng/ml. In June 1995, the PRL level was Four months after transplantation, thyrotropin function was normal without any -thyroxine (L-T4= 25 200 ng/ml despite of 15 mg/day bromocriptine (Figure 1) . 16 pg/ml; TSH=0.52 IU/l ). However, testosterone level remained low (1.3 ng/ml ) without treatment and Pituitary MRI was performed every 4 months (the last before transplantation was made in June 1995) gonadotropins were in the low normal range, responding normally to LHRH (LH=1.8-9.6 IU/l; and showed no significant modification of the size of the adenoma.
FSH=4.9-7.8 IU/l ). GH secretion was normal. In August 1995, the patient received a cadaver renal transplant. The immunosuppressive regimen combined Discussion azathioprine, corticosteroids (1 mg/kg solupred ) and antithymoglobulin during the first 14 days, with cyclosporine A introduction at day 10. Dopamine We report the case of a man with CRF and macroprolactinoma characterized by unusually high PRL (2.5 g/kg/min) was also infused continuously for 18 days. Improvement of renal function was delayed by (72 600 ng/ml ). Whereas bromocriptine treatment was only partially effective during maintenance haemodiaacute tubular necrosis, and haemodialysis remained necessary for 8 days. Because of an acute rejection at lysis, PRL levels return to normal immediately after renal transplantation. day 20 post-transplantation, steroid treatment was increased. The patient was discharged on day 40 with Before transplantation, we did not exclude that this patient had a macroadenoma, partially resistant to serum creatinine at 178 mmol/l, which stabilized thereafter at around 140 mmol/l. The hormonal treatment bromocriptine treatment, as it has been described in 10% of macroprolactinomas [8] . The patient received remained unchanged throughout this period.
The day before transplantation, prolactinaemia was a maximal dose of 15 mg/day bromocriptine. The lack of improvement in PRL levels when bromocriptine 8400 ng/ml. One week after transplantation, prolactin levels returned to normal range (4 ng/ml ) under was increased from 10 mg/day to 15 mg/day and the poor tolerance of high doses bromocriptine in this 15 mg/day of bromocriptine. One, 3, 6 and 9 months after transplantation, the patient's PRL level was patient undergoing dialysis, did not press us to increase the bromocriptine dose. Nevertheless, the hypothesis normal under the same treatment, thus confirming its stability ( Figure 1 ). In November 1995 (4 months after of a molecular resistance to bromocriptine itself does not explain the dramatic decrease in PRL levels after transplantation), a new pituitary MRI showed that 
